Precigen Inc
PGEN1.774USD
+0.104+6.23%
交易中 （美東）報價延遲15分鐘
523.57M總市值
虧損本益比TTM
關於 Precigen Inc 公司
Precigen, Inc. 是一家專注於發現和臨牀階段的生物製藥公司，致力於推進基因和細胞療法。該公司的專有技術平臺開發的產品候選物旨在針對其核心治療領域（免疫腫瘤學、自身免疫性疾病和傳染病）中的緊急和難治性疾病。該公司已開發出一系列針對多種適應症的療法。該公司通過兩個部門運營：生物製藥和 Exemplar。生物製藥部門主要由公司的法人實體 Precigen 和 ActoBio 以及來自非公司控制的公司的治療和治療平臺的特許權使用費權益組成。Exemplar 部門由 Exemplar Genetics LLC 組成，以 Precigen Exemplar (Exemplar) 的名義開展業務，這是其全資子公司，專注於開發用於醫療保健研究應用的研究模型和服務。
公司簡介
公司代碼PGEN
公司名稱Precigen Inc
上市日期Aug 08, 2013
CEODr. Helen Sabzevari, Ph.D.
員工數量143
證券類型Ordinary Share
年結日Aug 08
公司地址20374 Seneca Meadows Parkway
城市GERMANTOWN
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編20876
電話13015569900
網址https://precigen.com/
公司代碼PGEN
上市日期Aug 08, 2013
CEODr. Helen Sabzevari, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
520.43K
+32.30%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
176.84K
+253.14%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
59.03K
+279.40%
Mr. Cesar L. Alvarez
Mr. Cesar L. Alvarez
Independent Director
Independent Director
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
520.43K
+32.30%
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Service
1.11M
83.15%
Product
203.00K
15.14%
Other
23.00K
1.72%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
Service
1.11M
83.15%
Product
203.00K
15.14%
Other
23.00K
1.72%
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Third Security, LLC
39.41%
Merck Serono SA
6.99%
Patient Capital Management, LLC
5.89%
Adage Capital Management, L.P.
3.82%
BlackRock Institutional Trust Company, N.A.
3.24%
Other
40.65%
持股股東
持股股東
佔比
Third Security, LLC
39.41%
Merck Serono SA
6.99%
Patient Capital Management, LLC
5.89%
Adage Capital Management, L.P.
3.82%
BlackRock Institutional Trust Company, N.A.
3.24%
Other
40.65%
股東類型
持股股東
佔比
Venture Capital
39.41%
Investment Advisor
15.26%
Corporation
6.99%
Hedge Fund
6.47%
Investment Advisor/Hedge Fund
5.43%
Individual Investor
3.56%
Research Firm
0.41%
Bank and Trust
0.06%
Insurance Company
0.04%
Other
22.36%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
296
229.13M
77.63%
-805.74K
2025Q1
334
228.75M
77.50%
-12.95M
2024Q4
336
223.34M
76.44%
-15.36M
2024Q3
342
222.44M
77.88%
+21.14M
2024Q2
350
183.56M
71.33%
-22.34M
2024Q1
356
187.95M
73.95%
-17.15M
2023Q4
369
187.18M
73.43%
-12.81M
2023Q3
377
185.65M
75.06%
-11.67M
2023Q2
383
181.15M
73.32%
-8.55M
2023Q1
397
185.25M
75.25%
+14.81M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Third Security, LLC
116.34M
39.41%
-507.18K
-0.43%
Mar 31, 2025
Merck Serono SA
20.65M
6.99%
--
--
Mar 31, 2025
Patient Capital Management, LLC
17.37M
5.89%
-508.94K
-2.85%
Mar 31, 2025
Adage Capital Management, L.P.
11.28M
3.82%
+410.60K
+3.78%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.56M
3.24%
+209.48K
+2.24%
Mar 31, 2025
The Vanguard Group, Inc.
8.80M
2.98%
+465.47K
+5.59%
Mar 31, 2025
Iridian Asset Management LLC
4.59M
1.55%
-656.11K
-12.52%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.48M
1.18%
+179.75K
+5.45%
Mar 31, 2025
Sabzevari (Helen)
3.32M
1.12%
+557.91K
+20.22%
May 16, 2025
Parkman Healthcare Partners LLC
3.19M
1.08%
+3.19M
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Inspire Small/Mid Cap ESG ETF
0.19%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
Fidelity Enhanced Small Cap ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
查看更多
Inspire Small/Mid Cap ESG ETF
佔比0.19%
iShares Micro-Cap ETF
佔比0.05%
Invesco Nasdaq Biotechnology ETF
佔比0.05%
ProShares Ultra Nasdaq Biotechnology
佔比0.05%
Fidelity Enhanced Small Cap ETF
佔比0.02%
iShares Biotechnology ETF
佔比0.02%
ProShares UltraPro Russell2000
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
